Emmaus Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

REVENUES (Tables)

12 Months Ended

Dec. 31, 2019

Revenues by category were as follows (in thousands):

The following table summarizes the revenue allowance and accrual activities for the years ended December 31, 2019 and 2018 (in thousands):

	Trade Discounts, Allowances and Chargebacks			Government Rebates and Other Incentives			Returns		Total
Balance as of December 31, 2017	$	—		$	—		$	—	$	—
Provision related to sales in the current year		926			1,535			99		2,560
Credit and payments made		(842	)		(737	)		—		(1,579	)
Balance as of December 31, 2018		84			798			99		981
Provision related to sales in the current year		1,393			3,082			216		4,691
Credit and payments made		(1,249	)		(2,526	)		—		(3,775	)
Balance as of December 31, 2019		228			1,354			315		1,897

The following table sets forth information regarding customers that accounted for 10% or more of net revenues and account receivables:

	Revenue for year ended December 31,						Accounts receivables as of December 31,
	2019			2018			2019			2018
AmerisourceBergen Specialty Group		58	%		78	%		56	%		57	%
McKesson Plasma and Biologics LLC		23	%		14	%		31	%		25	%